<p>, /PRNewswire/ -- Akeso, Inc. (9926.HK)（&#34;Akeso&#34;或&#34;公司&#34;）今天宣布，其首个同类 PD-1/CTLA-4 双特异性抗体 cadonilimab 与化疗联合用于晚期胰腺导管腺癌（PDAC）的一线治疗的 COMPASSION-26 研究的积极 II 期结果在 2026 年美国癌症研究协会（AACR）年会上发布。</p>
<p>截至 2025 年 10 月 20 日的数据截止，cadonilimab 加化疗的组合在中位随访超过两年的情况下，继续提供强劲和持久的生存获益。在局部晚期疾病患者中，结果尤其显著，中位无进展生存期（PFS）达到 11.1 个月，中位总生存期（OS）超过 23 个月。该组的标志性生存率包括 12 个月 OS 率为 91.7% 和 24 个月 OS 率为 44.1%。</p>
<p>cadonilimab 方案在整体研究人群中也提供了强大的肿瘤控制。在可评估疗效的患者中（95% 至少有一次基线后肿瘤评估），客观缓解率（ORR）为 33.9%，疾病控制率（DCR）达到 96.4%。局部晚期和转移性疾病患者的反应率相似，表明两个亚组均有一致的获益。</p>
<p>未发现新的安全信号，cadonilimab 组合的整体安全性特征仍然良好且可控。</p>
<p>Cadonilimab 是全球首个获得批准的癌症免疫治疗双特异性抗体，已于 2022 年获得市场批准。在广泛的真实世界临床实践和多项 III 期研究中，它在所有患者群体中均显示出临床上有意义的获益，无论 PD-L1 表达状态如何，满足了重大的未满足医疗需求，并获得了医生和患者的广泛认可。</p>
<p>作为肿瘤免疫治疗 2.0 时代的基石疗法，cadonilimab 不仅在广泛的患者群体中提供了显著的临床获益优势，还在难治性疾病和免疫学上&#34;冷&#34;的肿瘤等困难治疗环境中展示了重要的突破潜力。Akeso 充分利用其在肿瘤学双特异性抗体开发方面的全球领导地位，继续解决重大未满足的临床需求，并推动具有变革性的治疗选择，为面临挑战的癌症患者提供帮助。</p>
<p><strong>关于 Akeso</strong></p>
<p>Akeso（HKEX: 9926.HK）是一家领先的生物制药公司，致力于全球首个或最佳创新生物药物的研究、开发、生产和商业化。公司成立于 2012 年，建立了以其四抗体技术平台、人工智能驱动的药物研发平台、双保护抗体药物偶联物（ADC）技术平台、双锁 T 细胞结合剂（TCE）技术平台、组织智能 siRNA/mRNA 技术平台和细胞治疗技术平台为中心的强大研发创新生态系统。在全球标准的 GMP 制造基础设施和高效、集成的商业化模式的支持下，公司已发展成为一家专注于创新解决方案的全球竞争力生物制药企业。凭借全面集成的多功能平台，Akeso 正在内部开发超过 50 个创新资产的强大管线，涵盖癌症、自身免疫疾病、炎症、代谢疾病和其他重大疾病。其中，27 个候选药物已进入临床试验（包括 15 个双特异性/多特异性抗体和双特异性 ADC）。此外，7 种新药已上市。通过高效和突破性的研发创新，Akeso 始终整合优质的全球资源，开发首个和最佳的新药，为全球患者提供可负担的治疗抗体，并不断创造更多的商业和社会价值，成为全球领先的生物制药企业。</p>
<p><strong>前瞻性声明</strong></p>
<p>Akeso, Inc.（9926.HK，&#34;Akeso&#34;）的本公告包含&#34;前瞻性声明&#34;。这些声明反映了 Akeso 管理层当前的信念和期望，并受到重大风险和不确定性的影响。这些声明并不旨在作为任何投资决策或购买 Akeso 证券的依据。不能保证本公告中提到的药物候选者或 Akeso 的其他管线候选者将获得所需的监管批准或实现商业成功。如果基础假设被证明不准确或风险或不确定性实现，实际结果可能与前瞻性声明中所述的有重大差异。</p>
<p>风险和不确定性包括但不限于一般行业状况和竞争；一般经济因素，包括利率和汇率波动；中国、美国及国际制药行业监管和医疗立法的影响；全球医疗成本控制的趋势；竞争对手获得的技术进步、新产品和专利；新产品开发中固有的挑战，包括获得监管批准；Akeso 准确预测未来市场状况的能力；制造困难或延误；国际经济的财务不稳定和主权风险；依赖于 Akeso 对创新产品的专利和其他保护的有效性；以及面临诉讼，包括专利诉讼和/或监管行动的风险。</p>
<p>Akeso 不承担任何义务，公开修订这些前瞻性声明，以反映本公告日期之后的事件或情况，法律要求的除外。</p>
<p>来源：Akeso, Inc.</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDIwJk5ld3NJdGVtSWQ9Q04zOTM0OCZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MjAyMjU0UFJfTkVXU19VU1BSX19fX19DTjM5MzQ4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDIwJk5ld3NJdGVtSWQ9Q04zOTM0OCZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MjAyMjU0UFJfTkVXU19VU1BSX19fX19DTjM5MzQ4"/></p>

AKRO

标普生物技术 ETF - SPDR

生物科技 ETF - VanEck Vectors

<p>Akeso, Inc. 宣布了其双特异性抗体 cadonilimab 在与化疗联合治疗晚期胰腺癌的 COMPASSION-26 研究中取得了积极的 II 期结果。研究显示显著的生存获益，局部晚期患者的中位无进展生存期为 11.1 个月，总生存期超过 23 个月。该治疗显示出 33.9% 的客观反应率和 96.4% 的疾病控制率，且安全性良好。Akeso 旨在利用其双特异性抗体的专业知识来满足肿瘤学领域未满足的临床需求</p>

<p>, /PRNewswire/ -- Akeso, Inc. (9926.HK) (&#34;Akeso&#34; or the &#34;Company&#34;) today announced that positive Phase II results from the COMPASSION-26 study evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy as first-line treatment for advanced pancreatic ductal adenocarcinoma (PDAC), were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Akeso, Inc. (9926.HK)（&#34;Akeso&#34;或&#34;公司&#34;）今天宣布，其首个同类 PD-1/CTLA-4 双特异性抗体 cadonilimab 与化疗联合用于晚期胰腺导管腺癌（PDAC）的一线治疗的 COMPASSION-26 研究的积极 II 期结果在 2026 年美国癌症研究协会（AACR）年会上发布。</p>
</div><p>As of the October 20, 2025 data cutoff, with a median follow-up of more than two years, the cadonilimab plus chemotherapy combination continued to deliver robust and durable survival benefits. Results were particularly strong in patients with locally advanced disease, where the median PFS reached 11.1 months and the median OS exceeded 23 months. Landmark survival rates in this group included a 12-month OS rate of 91.7% and a 24-month OS rate of 44.1%.</p>
<div class="lb-trans"><p>截至 2025 年 10 月 20 日的数据截止，cadonilimab 加化疗的组合在中位随访超过两年的情况下，继续提供强劲和持久的生存获益。在局部晚期疾病患者中，结果尤其显著，中位无进展生存期（PFS）达到 11.1 个月，中位总生存期（OS）超过 23 个月。该组的标志性生存率包括 12 个月 OS 率为 91.7% 和 24 个月 OS 率为 44.1%。</p>
</div><p>The cadonilimab regimen also provided strong tumor control across the overall study population. Of the patients evaluable for efficacy (95% had at least one post-baseline tumor assessment), the objective response rate (ORR) was 33.9% and the disease control rate (DCR) reached 96.4%. Response rates were similar between patients with locally advanced and metastatic disease, indicating consistent benefit across both subgroups.</p>
<div class="lb-trans"><p>cadonilimab 方案在整体研究人群中也提供了强大的肿瘤控制。在可评估疗效的患者中（95% 至少有一次基线后肿瘤评估），客观缓解率（ORR）为 33.9%，疾病控制率（DCR）达到 96.4%。局部晚期和转移性疾病患者的反应率相似，表明两个亚组均有一致的获益。</p>
</div><p>No new safety signals were identified, and the overall safety profile of the cadonilimab combination remained favorable and manageable.</p>
<div class="lb-trans"><p>未发现新的安全信号，cadonilimab 组合的整体安全性特征仍然良好且可控。</p>
</div><p>Cadonilimab is the world's first approved bispecific antibody for cancer immunotherapy, having received marketing approval in 2022. In extensive real-world clinical practice and multiple Phase III studies, it has demonstrated clinically meaningful benefit across all patient populations regardless of PD-L1 expression status, addressing a significant unmet medical need and earning broad recognition from physicians and patients.</p>
<div class="lb-trans"><p>Cadonilimab 是全球首个获得批准的癌症免疫治疗双特异性抗体，已于 2022 年获得市场批准。在广泛的真实世界临床实践和多项 III 期研究中，它在所有患者群体中均显示出临床上有意义的获益，无论 PD-L1 表达状态如何，满足了重大的未满足医疗需求，并获得了医生和患者的广泛认可。</p>
</div><p>As a cornerstone therapy in the era of tumor immunotherapy 2.0, cadonilimab not only offers the significant advantage of clinical benefit across broad patient populations, but has also demonstrated important breakthrough potential in difficult-to-treat settings, including immunotherapy-refractory disease and immunologically &#34;cold&#34; tumors. Akeso is fully leveraging its global leadership in bispecific antibody development for oncology to continue addressing major unmet clinical needs and advancing transformative treatment options for patients with challenging cancers.</p>
<div class="lb-trans"><p>作为肿瘤免疫治疗 2.0 时代的基石疗法，cadonilimab 不仅在广泛的患者群体中提供了显著的临床获益优势，还在难治性疾病和免疫学上&#34;冷&#34;的肿瘤等困难治疗环境中展示了重要的突破潜力。Akeso 充分利用其在肿瘤学双特异性抗体开发方面的全球领导地位，继续解决重大未满足的临床需求，并推动具有变革性的治疗选择，为面临挑战的癌症患者提供帮助。</p>
</div><p><strong>About Akeso</strong></p>
<div class="lb-trans"><p><strong>关于 Akeso</strong></p>
</div><p>Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has established a robust R&amp;D innovation ecosystem centered on its Tetrabody antibody technology platform, AI-powered drug R&amp;D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient, integrated commercialization model, the company has evolved into a globally competitive biopharmaceutical focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 27 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&amp;D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.</p>
<div class="lb-trans"><p>Akeso（HKEX: 9926.HK）是一家领先的生物制药公司，致力于全球首个或最佳创新生物药物的研究、开发、生产和商业化。公司成立于 2012 年，建立了以其四抗体技术平台、人工智能驱动的药物研发平台、双保护抗体药物偶联物（ADC）技术平台、双锁 T 细胞结合剂（TCE）技术平台、组织智能 siRNA/mRNA 技术平台和细胞治疗技术平台为中心的强大研发创新生态系统。在全球标准的 GMP 制造基础设施和高效、集成的商业化模式的支持下，公司已发展成为一家专注于创新解决方案的全球竞争力生物制药企业。凭借全面集成的多功能平台，Akeso 正在内部开发超过 50 个创新资产的强大管线，涵盖癌症、自身免疫疾病、炎症、代谢疾病和其他重大疾病。其中，27 个候选药物已进入临床试验（包括 15 个双特异性/多特异性抗体和双特异性 ADC）。此外，7 种新药已上市。通过高效和突破性的研发创新，Akeso 始终整合优质的全球资源，开发首个和最佳的新药，为全球患者提供可负担的治疗抗体，并不断创造更多的商业和社会价值，成为全球领先的生物制药企业。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This announcement by Akeso, Inc. (9926.HK, &#34;Akeso&#34;) contains &#34;forward-looking statements&#34;. These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.</p>
<div class="lb-trans"><p>Akeso, Inc.（9926.HK，&#34;Akeso&#34;）的本公告包含&#34;前瞻性声明&#34;。这些声明反映了 Akeso 管理层当前的信念和期望，并受到重大风险和不确定性的影响。这些声明并不旨在作为任何投资决策或购买 Akeso 证券的依据。不能保证本公告中提到的药物候选者或 Akeso 的其他管线候选者将获得所需的监管批准或实现商业成功。如果基础假设被证明不准确或风险或不确定性实现，实际结果可能与前瞻性声明中所述的有重大差异。</p>
</div><p>Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.</p>
<div class="lb-trans"><p>风险和不确定性包括但不限于一般行业状况和竞争；一般经济因素，包括利率和汇率波动；中国、美国及国际制药行业监管和医疗立法的影响；全球医疗成本控制的趋势；竞争对手获得的技术进步、新产品和专利；新产品开发中固有的挑战，包括获得监管批准；Akeso 准确预测未来市场状况的能力；制造困难或延误；国际经济的财务不稳定和主权风险；依赖于 Akeso 对创新产品的专利和其他保护的有效性；以及面临诉讼，包括专利诉讼和/或监管行动的风险。</p>
</div><p>Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.</p>
<div class="lb-trans"><p>Akeso 不承担任何义务，公开修订这些前瞻性声明，以反映本公告日期之后的事件或情况，法律要求的除外。</p>
</div><p>SOURCE Akeso, Inc.</p>
<div class="lb-trans"><p>来源：Akeso, Inc.</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDIwJk5ld3NJdGVtSWQ9Q04zOTM0OCZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MjAyMjU0UFJfTkVXU19VU1BSX19fX19DTjM5MzQ4" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CN39348&amp;Transmission_Id=202604202254PR_NEWS_USPR_____CN39348&amp;DateId=20260420"/></p>

22:54 ETCadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026

prnewswire

Akero Therapeutics

动态生物技术与基因组 ETF - Invesco

医药突破 ETF - ALPS

医疗业 ETF - Vanguard

标普生物技术 3 倍做多 - Direxion

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

Invesco Nasdaq Biotechnology ETF

基因改革 ETF - ARK

美国制药 ETF - iShares

医疗业 ETF - SPDR

康方生物

Cadonilimab 联合治疗在局部晚期胰腺癌中展示出有前景的生存益处：COMPASSION-26 二期数据在 2026 年 AACR 会议上展示